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cognitive enhancement Therapy 
improves Frontolimbic regulation 
of emotion in alcohol and/or 
cannabis Misusing schizophrenia: 
a Preliminary study
Jessica A. Wojtalik1* , Susan S. Hogarty2 , Jack R. Cornelius2 , Mary L. Phillips2 ,  
Matcheri S. Keshavan3 , Christina E. Newhill1 and Shaun M. Eack1,2
1 School of Social Work, University of Pittsburgh, Pittsburgh, PA, USA, 2 Department of Psychiatry, School of Medicine, 
University of Pittsburgh, Pittsburgh, PA, USA, 3 Department of Psychiatry, Harvard Medical School, Boston, MA, USA
Individuals with schizophrenia who misuse substances are burdened with impairments in 
emotion regulation. Cognitive enhancement therapy (CET) may address these problems 
by enhancing prefrontal brain function. A small sample of outpatients with schizophrenia 
and alcohol and/or cannabis substance use problems participating in an 18-month ran-
domized trial of CET (n = 10) or usual care (n = 4) completed posttreatment functional 
neuroimaging using an emotion regulation task. General linear models explored CET 
effects on brain activity in emotional neurocircuitry. Individuals treated with CET had 
significantly greater activation in broad regions of the prefrontal cortex, limbic, and striatal 
systems implicated in emotion regulation compared to usual care. Differential activation 
favoring CET in prefrontal regions and the insula mediated behavioral improvements in 
emotional processing. Our data lend preliminary support of CET effects on neuroplas-
ticity in frontolimbic and striatal circuitries, which mediate emotion regulation in people 
with schizophrenia and comorbid substance misuse problems.
Keywords: schizophrenia, alcohol misuse, cannabis misuse, emotion regulation, brain, cognitive enhancement 
therapy
inTrODUcTiOn
Substance misuse among individuals with schizophrenia is substantially higher compared to the 
general population (1, 2), which has been linked to problems in emotion dysregulation (3–5), 
defined as the inability to tolerate and appropriately manage emotions, particularly negative affects. 
Individuals with schizophrenia who misuse substances tend to function worse in the community 
(6), experience lower quality of life (7), treatment non-adherence (8, 9), and have higher rates of 
relapse often leading to emergency room contact and/or hospitalization (10). Indeed, the experi-
ence of overall greater severity of the illness in this population often results in two to three times 
more hospitalizations than patients with schizophrenia who do not abuse substances (11). Misuse 
of substances has been proposed to exacerbate symptoms (12), such that positive symptoms tend to 
be particularly more severe in people with schizophrenia and comorbid substance misuse diagnoses 
(13). Cannabis and alcohol have been indicated to be the two most commonly misused substances 
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among individuals with schizophrenia (2). While literature on the 
relationship between substance misuse and cognitive functioning 
in schizophrenia have been mixed and difficult to interpret (14), 
generally it can be inferred that individuals with schizophrenia 
who misuse alcohol or cannabis experience cognitive deficits 
(15, 16). In a recent randomized-controlled trial, we found that 
cognitive enhancement therapy [CET (17)] resulted in significant 
improvements in emotion regulation abilities among people with 
schizophrenia and alcohol and/or cannabis use problems, as well 
as significant reductions in alcohol use (18). CET is a psycho-
social cognitive remediation intervention (19) that integrates 
60 h of computer-based training targeted at improving attention, 
memory, and problem solving with 45 structured social-cognitive 
group sessions designed to improve abilities, such as perspective 
taking, social context appraisal, and emotion regulation abilities. 
Examination of the neurobiological underpinnings of improved 
emotion regulation associated with cognitive remediation can 
yield important information about the plasticity of neural mecha-
nisms that can support addiction and psychiatric recovery in this 
population.
The affect regulation model has been one of the most empiri-
cally supported conceptualizations of the nature of high rates 
of substance misuse among individuals with schizophrenia 
(3, 5). This model proposes that individuals with schizophrenia 
who are high in trait negative affect are more likely to misuse 
substances as a way to cope and regulate the intensity of nega-
tive emotional states (3, 4). In support of this model, numerous 
studies have found that people with schizophrenia report that 
they misuse substances to relieve or buffer dysregulated negative 
emotions (20, 21). The brain circuitry for supporting successful 
emotion regulation involves regions in the prefrontal cortex, 
limbic system, and the striatum (22–24), which are also regions 
thought to be impacted by the pharmacological effects of addic-
tion (25) and the symptoms of schizophrenia (26). For example, 
dysfunctional communication between the nucleus accumbens, 
frontal cortex, and hippocampus observed in non-substance 
abusing schizophrenia patients is similar to the substance abuse-
related neurobiological changes observed in primary additive 
disorders (26).
Based on the aforementioned findings, we posit that par-
ticipation in cognitive remediation interventions may alter 
functioning of the frontal, limbic, and striatal neurocircuitry to 
support improvement in emotion regulation in individuals with 
schizophrenia and substance misuse comorbidity. Meta-analytic 
evidence is supportive of neuroplasticity or “brain changing” 
effects of cognitive remediation interventions, where individuals 
with schizophrenia have demonstrated increased brain function 
in prefrontal, limbic, and striatal regions following treatment 
(27). Additionally, protection against gray matter loss in lim-
bic regions has been observed in early course schizophrenia 
outpatients treated with CET (28). Both increased neural 
activation and gray matter in frontolimbic and striatal regions 
were associated with improved cognitive and socioemotional 
outcomes (27, 28). Although substance misuse is often an exclu-
sion criterion in cognitive remediation trials (29), such findings 
suggest that these treatments, such as CET, may have the ability 
to strengthen neurobiological functions that govern emotional 
circuitry in individuals with schizophrenia and substance 
misuse comorbidity (29). However, no study has examined the 
neurobiological effects of cognitive remediation in people with 
schizophrenia who misuse substances.
Identifying biomarkers of therapeutic mechanisms in the 
treatment of individuals with schizophrenia is imperative for the 
continued understanding of the pathophysiology of the illness 
and the impact of substance misuse. More importantly, under-
standing the neurobiological effects of cognitive remediation 
could reinforce the utility of such interventions (19) to intervene 
with the diversity of challenges people with schizophrenia face, 
including substance misuse. Therefore, this preliminary study 
sought to explore the posttreatment neurobiological impact of 
CET on frontolimbic and striatal brain functioning during the 
effortful regulation of emotion in a small sample of individuals 
with schizophrenia who misuse alcohol and/or cannabis, the two 
most commonly abused substances in this population (2). The 
degree to which posttreatment brain functioning during emotion 
regulation was related to longitudinal behavioral improvements 
in emotion processing was also investigated.
MaTerials anD MeThODs
Participants
A total of 14 individuals diagnosed with schizophrenia (n = 10) 
or schizoaffective disorder (n = 4) and alcohol and/or cannabis 
misuse problems were included in an 18-month randomized 
feasibility study (NCT01292577) of CET compared to treat-
ment as usual [TAU (18)]. All participants provided written 
informed consent prior to their participation. The study proto-
col was approved by the University of Pittsburgh Institutional 
Review Board, was reviewed annually, and was registered in 
the national clinical trials database. There were 31 participants 
included in the larger randomized feasibility trial of CET (18), 
with 14 subjects (n =  10 CET and n =  4 TAU) available for 
functional magnetic resonance imaging (fMRI) after complet-
ing treatment. The reasons for participants being unavailable 
for scanning included withdrawing consent (n = 5), incarcera-
tion (n = 1), cocaine abuse (n = 1), symptom instability (n = 4), 
heroin dependence (n = 1), lack of interest in being scanned 
(n = 2), unable to contact (n = 2), and ferromagnetic objects in 
the body (n = 1). Inclusion criteria for the participants were (1) 
age between 18 and 60, (2) diagnosis of schizophrenia or schiz-
oaffective disorder based on the Structured Clinical Interview 
for the DSM-IV [SCID (30)], (3) presentation of significant 
cognitive and social disability on the Cognitive Styles and 
Social Cognition Eligibility Interview (31), (4) an Addiction 
Severity Index (32) score of moderate or higher (≥4) addiction 
severity for cannabis or alcohol use, (5) stabilization on antipsy-
chotic medications, (6) an IQ ≥ 80, (7) the ability to speak and 
read fluent English, (8) no current cocaine, amphetamine, or 
opioid abuse or dependence, (9) not receiving substance abuse 
pharmacotherapies (e.g., naltrexone), (10) no significant cogni-
tive impairment caused by the presence of a persistent medical 
condition, (11) no persistent suicidal or homicidal behavior, 
and (12) free of any MRI contraindications.
TaBle 1 | Baseline characteristics of ceT and TaU participants with schizophrenia who misuse alcohol and/or cannabis presented as N (%) or M (sD).
characteristic Total (n = 14)  ceT (n = 10)  TaU (n = 4) pa
Age (years) 38.7 (13.26) 41.20 (13.65) 32.50 (11.45) 0.285
Sex (male) 8 (57%) 6 (60%) 2 (50%) 1.00
Race: Caucasian 7 (50%) 6 (60%) 1 (25%)
       African-American 6 (43%) 4 (40%) 2 (50%) 0.271
       Asian 1 (7%) – 1 (25%)
IQ 101.43 (11.69) 102.70 (13.6) 98.25 (4.27) 0.541
Attended college 11 (79%) 8 (80%) 3 (75%) 0.728
Education (years) 14.50 (1.61) 14.6 (1.65) 14.25 (1.71) 1.00
Not employed 11 (79%) 7 (70%) 4 (100%) 0.505
Illness length (years) 14.93 (10.38) 15.50 (10.52) 13.5 (11.45) 0.759
BPRS total 42.93 (10.26) 40.90 (7.77) 48.0 (15.08) 0.258
ASI: alcohol 4.5 (2.68) 4.40 (3.10) 4.75 (1.50) 0.835
ASI: drug 3.14 (2.14) 3.0 (2.49) 3.50 (1.00) 0.710
Principle diagnosis
Schizophrenia 10 (71%) 8 (80%) 2 (50%)
Schizoaffective 4 (29%) 2 (20%) 2 (50%) 0.520
Substance abuse or dependence diagnosis 12 (86%) 9 (90%) 3 (75%) 0.505
Alcohol dependence 7 (50%) 5 (50%) 2 (50%) 1.00
Alcohol abuse 2 (14%) 2 (20%) – 1.00
Cannabis dependence 7 (50%) 5 (50%) 2 (50%) 1.00
Cannabis abuse 1 (7%) – 1 (25%) 0.286
Daily substance use among active users
Alcohol use occasions per day 2.15 (2.39) 2.59 (2.42) 1.07 (2.14) 0.301
Cannabis use occasions per day 0.34 (0.85) 0.48 (0.98) – 0.363
Antipsychotic medication
Atypical 11 (79%) 7 (70%) 4 (100%) 0.505
Typical 3 (21%) 3 (30%) –
Dose (CPZ equivalent) 449.52 (360.69) 402.67 (370.68) 566.67 (354.86) 0.464
Adherent 13 (93%) 9 (90%) 4 (100%) 1.00
MSCEIT total score
Baseline 87.33 (14.98) 85.94 (14.27) 90.82 (18.40) 0.602
Posttreatment 91.17 (15.53) 92.19 (14.98) 88.61 (18.96) 0.713
ER-40 correct response
Baseline 32.29 (3.45) 31.90 (3.96) 33.25 (1.71) 0.530
Posttreatment 33.18 (3.05) 33.35 (3.54) 32.75 (1.50) 0.754
ASI, Addiction Severity Index; BPRS, Brief Psychiatric Rating Scale; CPZ, chlorpromazine, MSCEIT, The Mayer–Salovey–Caruso Emotional Intelligence Test; ER-40, Penn Emotion 
Recognition Test-40.
aResults from independent sample t-tests or Fisher’s exact tests, two-tailed.
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See Table 1 for a full description of participant characteristics. 
Overall, participants with fMRI data had an average age of 38.71 
(SD =  13.26) years, were ill for an average duration of 14.93 
(SD =  10.38) years, and completed 14.50 (SD =  1.61) years of 
education. Eighty-six percent (n = 12) of the participants also had 
a comorbid alcohol and/or cannabis misuse diagnosis based on 
the SCID (30). Two participants did not meet SCID criteria for a 
comorbid alcohol and/or cannabis misuse diagnosis, but met for 
the inclusion criteria of an Addiction Severity Index (32) score of 
moderate or higher (≥4) addiction severity for cannabis or alcohol 
use. The participants were ethnically diverse (seven Caucasian, 
six African American, and one Asian) and a little more than half 
were male (n =  8, 57%). Although the majority of the partici-
pants had some college education (n = 11, 79%) and most were 
not employed (n = 11, 79%) at the time of baseline assessment. 
Participants randomized to either CET (n = 10) or TAU (n = 4) 
did not significantly differ with regard to the above demographic 
variables (all p > 0.271), baseline IQ (p = 0.541), BPRS total score 
(p = 0.258), antipsychotic medication dose (p = 0.464), type of 
antipsychotic mediation (0.505), or adherence to antipsychotic 
medication (p = 1.00). The observation of a non-significant dif-
ference between CET and TAU participants with regard to type 
of antipsychotic medication is important given that typical and 
atypical antipsychotics may impact brain functioning differently 
(33). The CET participants were non-significantly older than the 
TAU participants, and there were more Caucasian participants 
in the CET group (n =  6, 60%) compared to only one (25%) 
Caucasian participant in the TAU group. Consequently, age and 
race were included as confounding covariates in all analyses of the 
differential effects of CET compared to TAU on brain function.
emotional Faces n-Back Task
Brain functioning during the effortful regulation of emotion was 
elicited using an emotional faces n-back task, which is a modified 
version of the standard working memory n-back task including 
0-back and 2-back working memory conditions (34). An n-back 
FigUre 1 | example of a 2-back happy face distracter condition from the emotional faces n-back task. [Reproduced with permission from Ladouceur 
et al. (34)].
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task is one that asks participants to respond when they view a 
stimulus (e.g., letter) that is the same as that presented n trails 
previously. In addition to the working memory conditions (0-back 
and 2-back), four emotional valence distracter conditions (no 
faces, happy faces, fearful faces, and neutral faces) were presented 
to participants. Faces were flanked on each side of the n-back letter 
stimuli (Figure  1). The faces were from the NimStim dataset in 
grayscale (35), were normalized for size and luminance, and bal-
anced by gender. Both working memory and emotional valence 
conditions were presented in randomized blocks of 12 trials 
each. By directing participants’ attention to the working memory 
components of the task, participants were required to inhibit their 
response to the emotional stimuli in order to successfully complete 
the n-back tasks (36), and thus this task is considered a test of 
effortful emotion regulation. Each block started with instructions 
indicating the working memory condition (0-back or 2-back) pre-
sented on the screen for 3500 ms, which was followed by the target 
stimulus (letters) presented flanked by the different emotional 
valence distracter conditions (happy, fearful, neutral, or no face) 
for 500 ms, with an interstimulus interval jittered at an average of 
3500 ms. The total task time was 6 min and 56 s with each emotional 
valence distracter condition presented once for both the 0-back and 
2-back conditions. All the participants completed two runs of the 
emotional faces n-back paradigm, with the exception of one TAU 
participant that completed one run. Since the focus of this research 
was on emotion regulation during effortful cognitive processing, 
only data from the effortful 2-back condition were analyzed.
image acquisition and Processing
A 3-T Siemens Verio whole-body scanner with a 12-chan-
nel head coil was used to collect structural and functional 
neuroimaging data at the Scientific Imaging and Brain Research 
Center at Carnegie Mellon University. Functional MRI data 
were acquired using an echo T2*-weighted sequence with real-
time motion correction (3.2  mm ×  3.2  mm ×  3.2  mm voxel 
size, TR =  2000  ms, TE =  30  ms, bandwidth =  2298  Hz/px, 
FOV = 205 mm, flip angle = 79°, 64 × 64 matrix, 36 slices, slice 
thickness = 3.2 mm).
Statistical Parametric Mapping Software, version 8 (SPM8; 
Wellcome Department of Cognitive Neurology, Institute of 
Neurology, London, UK) was used to preprocess imaging data. 
The images were normalized to a common Montreal Neurological 
Institute (MNI) coordinate space using an indirect normalization 
pipeline, with parameters obtained from a high-resolution T1 
structural image. Images were smoothed with an 8-mm full-
width at half maximum Gaussian kernel. Signal and movement 
outliers were identified using the Artifact Detection Tool (37) 
software package and entered into each participant’s first-level 
general linear model as regressors of no interest.
emotion Processing Behavioral Measures
In addition to assessing brain functioning during effortful emo-
tion regulation measured by the emotional faces n-back task 
outlined above, behavioral measures of emotion processing 
were also utilized in the parent study (18) to examine behavioral 
emotion processing skills at pre- and posttreatment. The Mayer–
Salovey–Caruso Emotional Intelligence Test [MSCEIT (38)] 
and the Penn Emotion Recognition Test-40 [ER-40 (39)] were 
the measures used to assess emotion processing. Noteworthy, 
brain regions important for emotion processing, which includes 
emotion regulation, such as limbic areas, have been shown to be 
associated with performance on both these measures (40, 41).
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The MSCEIT is a 141-item performance-based measure of 
emotion processing and management (e.g., emotional intelli-
gence) that is administered on the computer (42). Performance 
scores are based on a large normative sample scale (M = 100, 
SD =  15), with a higher score indicating a better emotional 
intelligence quotient (38). The MSCEIT is a recommended 
measure of the National Institute of Mental Health’s com-
mittee on Measurement and Treatment Research to Improve 
Cognition in Schizophrenia [NIMH-MATRICS (43)] and has 
been shown to have good reliability and sufficient construct 
and concurrent validity (43, 44). The ER-40 is also a frequently 
utilized measure of emotion processing in schizophrenia, 
as it has good psychometric properties (45) and is able to 
discriminate between healthy controls and individuals with 
schizophrenia (39). The ER-40 is a forced-choice, computer-
administered assessment of the ability to accurately recognize 
different emotions. The task involves a series of 40 happy, 
sad, angry, fearful, or neutral (non-emotional) faces. Scores 
represent number of correct responses, with a higher score 
indicating better performance.
TreaTMenTs
Medication
All participants were maintained on antipsychotic medications 
approved for the treatment of schizophrenia or schizoaffective 
disorder as prescribed by their treating psychiatrist. Table 1 lists 
antipsychotic medication characteristics of the participants.
cognitive enhancement Therapy
Cognitive enhancement therapy is a performance-based, 
comprehensive, developmental approach to the remediation 
of social-cognitive and neurocognitive deficits in participants 
with schizophrenia (17). CET consists of 60  h of weekly 
computer-based neurocognitive training to in attention, 
memory and problem-solving and 45 small-group sessions to 
address social-cognitive deficits that limit functional recovery 
from schizophrenia. To encourage socialization, neurocognitive 
training is implemented in patient pairs and conducted with 
coaching from a CET therapist. One-hour neurocognitive train-
ing sessions begin with Ben-Yishay’s Orientation Remediation 
Module (46) to improve different aspects of attention and speed 
of processing. Following ~3 months of attention training, 3–4 
participants combine to form a social-cognitive group. The 1.5-h 
social-cognitive group sessions utilize experiential learning 
approaches to teach a wide range of social-cognitive abilities 
designed to enhance social wisdom and interpersonal success. 
Key theoretically driven components of the social-cognitive 
groups include perspective-taking, social gist abstraction, non-
verbal communication, emotion management, and foresight-
fulness. The social-cognitive group curriculum encourages 
participants to engage in activities that include responding 
to unrehearsed social exchanges, presenting homework, par-
ticipating in social-cognitive exercises, providing feedback to 
others, and leading homework review. Neurocognitive training 
in memory and problem-solving using PSSCogReHab (47) 
software proceeds concurrently with the social-cognitive groups 
after the conclusion of attention training. A complete descrip-
tion of CET has been provided elsewhere (17).
Treatment as Usual
Treatment as usual served as the comparison treatment condi-
tion in this randomized feasibility trial of CET for schizophrenia 
participants who misuse substances. TAU consisted of traditional 
social services and mental health programs, which included 
psychiatric services, case management, individual supportive 
therapy, vocational rehabilitation, dual diagnosis treatment 
programs, and other community-based treatments for substance 
use. All efforts were made to link both CET and TAU participants 
with necessary mental health and substance abuse services while 
participating in the study.
PrOceDUres
Participants were recruited from Western Psychiatric Institute 
and Clinic and other community clinics at Pittsburgh, PA, 
USA. Potential participants were screened for eligibility using 
the SCID (30), the Ammons Quick IQ Test (48), the Addiction 
Severity Index (32), and the Cognitive Style and Social Cognition 
Eligibility Interview (31). Those participants meeting inclusion 
criteria were then randomized to receive 18 months of either CET 
or TAU. Individuals were then assessed every 6  months using 
the aforementioned behavioral emotion processing measures. A 
subset of 14 participants (n =  10 CET, n =  4 TAU) completed 
posttreatment fMRI scanning. Neuroimaging assessments were 
only available posttreatment as part of a separate pilot study that 
became available near the end of the larger feasibility trial of 
CET for alcohol and/or cannabis misusing schizophrenia (18). 
See Eack et al. (18) for details on this larger feasibility trial, such 
as the randomization procedures and the enrollment diagram. 
All participants provided written informed consent prior to their 
participation. The study protocol was approved by the University 
of Pittsburgh Institutional Review Board, was reviewed annu-
ally, and was registered in the national clinical trials database 
(NCT01292577).
Data analysis
Functional neuroimaging data are inherently hierarchical in 
nature, with brain images (collected every 2  s) nested within 
individuals in a time series. Analysis proceeds by first estimating 
the effects of task condition on brain activity for each individual 
(first-level analysis) and then subjecting those contrasts to group 
(second-level) analyses (49). SPM8 was utilized for first- and 
second-level voxel-based analyses to examine the differential 
posttreatment effects of CET compared to TAU on emotion 
regulation-related brain functioning. First-level analyses con-
sisted of modeling neural responses during each condition of 
the emotional faces n-back task with general linear models in 
each of the participants. First-level models also included the 
signal and motion outliers identified by the Artifact Detection 
Tool as covariates (37). First-level contrasts (happy face vs. no 
face, fearful face vs. no face, and neutral face vs. no face) were 
then entered into a second-level group analysis based on a two 
(CET vs. TAU) ×  three (happy face vs. no face, fearful face vs. 
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no face, and neutral face vs. no face) general linear model. To 
control the effect of general visual stimulation, the second-level 
contrasts compared emotional faces to neutral faces [e.g., (happy 
vs. no face)–(neutral vs. no face)]. As mentioned above, second-
level models included age and race as confounding covariates. 
A single region of interest mask was created in the Wake Forest 
University PickAtlas toolbox (50) with anatomical definitions 
provided by Tzourio-Mazoyer, Landeau (51). Regions of interest 
included frontolimbic and striatal areas, which were the bilat-
eral amygdala, insula, dorsolateral prefrontal cortex (DLPFC), 
ventromedial prefrontal cortex, orbitofrontal cortex, striatum, 
nucleus accumbens, and the anterior cingulate cortex. These 
regions have been repeatedly implicated in the regulation of emo-
tion (22, 24, 36, 52). Due to the conservativeness of voxel-wise 
multiple comparison corrections in small samples (53), Type I 
error was controlled using a cluster-extent thresholding method. 
Cluster-level correction with a small sample may provide the best 
balance between type I and type II error (54). Based on 10,000 
Monte Carlo simulations executed in 3dClustSim (55), type I 
error was indicated to be controlled at an α-level of 0.05 using a 
combined threshold of a voxel extent of 34 and an uncorrected 
p of 0.001.
Associations between differential posttreatment effects dur-
ing emotion regulation-related brain functioning and changes 
in behavioral emotion regulation performance from pre- to post-
treatment were analyzed with bivariate correlations and mediator 
models executed in R 3.1.2 (56). It was determined that age, race, 
and antipsychotic medication dose were not significantly related 
to emotion processing behavioral performance and emotion 
regulation-related brain functioning. Therefore, these variables 
were not included as covariates to retain statistical power in cor-
relations and mediator models. Average magnitude estimates per 
region of interest per participant were extracted using MarsBar, 
version 0.44 [http://marsbar.sourceforge.net (57)] from the 
above imaging analysis to be utilized for correlation and media-
tion analyses. A path analysis approach was used for the media-
tion analysis (58), which was based on the mediator-analytic 
framework presented by Kraemer et  al. (59) for randomized 
clinical trials. Mediator models were constructed with a series of 
linear models (60) that analyzed the indirect effects of treatment 
assignment (predictor) on longitudinal changes in emotion pro-
cessing behavioral performance (outcome) through posttreat-
ment emotion regulation-related brain functioning (mediator). 
This was accomplished by computing the association between 
(1) treatment assignment and emotion regulation-related brain 
functioning, (2) emotion regulation-related brain function 
and longitudinal changes in emotion processing behavioral 
performance, and (3) treatment assignment and longitudinal 
changes in emotion processing behavioral performance. Based 
on MacKinnon et al. (61), the magnitude and significance of the 
mediation effects was estimated using an asymptotic z′ test of 
indirect effects. Logarithmic transformations were used to cor-
rect any variables with significantly skewed distributions prior 
to analysis, which included the left inferior orbital frontal cortex, 
right DLPFC (BA 46), and reaction time from the emotional 
faces n-back. Missing data were handled with an expectation-
maximization approach (62).
resUlTs
emotional Faces n-Back Task 
Performance
Reaction time and accuracy performance on the emotional faces 
n-back task was also analyzed in R with mixed-effects models 
examining group (CET vs. TAU), working memory loading 
(0-back vs. 2-back) and emotional distracter valence (happy vs. 
fearful vs. neutral vs. no faces) effects. One TAU participant had 
accuracy data available but did not have recorded reaction time 
data due to technical issues. Investigation of task performance 
on the emotional faces n-back task during scanning revealed 
that participants had neither overall high accuracy, with no 
significant group (p =  0.228) or emotional distracter valence 
differences (p = 0.803) nor were there any significant group by 
emotional distracter valence interactions (p = 0.921), group by 
working memory loading interactions (p  =  0.369), or group 
by emotional distracter valence by working memory loading 
interactions (p = 0.918). Accuracy was high across both groups 
of participants, however, significantly lower for the 2-back 
condition (93%) compared to the 0-back condition (97%), 
χ2 (1, N = 14) = 9.68, p = 0.002.
Overall, participants did not significantly differ in reaction 
times with regard to group assignment (p = 0.695). With regard 
to the working memory loading condition, the participants 
had significantly slower reaction times during the 2-back 
condition (M = 6.73 mslog, SE = 0.06) compared to the 0-back 
condition (M = 6.44 mslog, SE = 0.06), χ2 (1, N = 13) = 72.81, 
p <  0.001. CET and TAU participants had similar reaction 
times during the 0-back (CET: M = 6.44 mslog, SE = 0.05; TAU: 
M = 6.42 mslog, SE = 0.10), but during the 2-back condition, 
the CET participants had significantly slower reaction times 
(M = 6.78 mslog, SE = 0.05) compared to the TAU participants 
(M = 6.68 mslog, SE = 0.10), χ2 (1, N = 13) = 3.86, p = 0.049. 
Participants did neither significantly differ in reaction times 
with regard to emotional valence distracters (p =  0.058) nor 
were significant interactions observed for group by emotional 
distracter valence (p  =  0.415) or group by emotional dis-
tracter valence by working memory loading (p = 0.491). Such 
results are confirmatory that participants were paying attention 
to the task and any differences in brain functioning elicited 
during the task are not due to differential inability to complete 
the task.
Posttreatment effects of ceT on 
Frontolimbic and striatal Brain 
Functioning During effortful emotion 
regulation
Region-of-interest voxel-based analyses were conducted using 
a 2 (CET vs. TAU) ×  3 (happy vs. no face, fearful vs. no face, 
and neutral vs. no face) general linear model to investigate post-
treatment brain differences between CET and TAU participants 
during effortful emotion regulation. No significant interaction 
effects were observed with regard to the emotional distracter 
conditions, and thus the main effects of treatment group were 
examined. Compared to the TAU group, CET participants 
TaBle 2 | Differential activation during the emotional faces n-back task observed between ceT and TaU participants at posttreatment.
region Ba Mni coordinates cluster size z p Direction
L inferior orbital frontal 47, 13 −50 24 −4 530 4.61 <0.001
CET > TAUL insula
L ventromedial prefrontal
R putamen/caudate – 26 22 2 160 4.56 <0.001 CET > TAU
R inferior/middle/superior orbital frontal 47 44 52 −2 91 3.73 <0.001 CET > TAU
R ventromedial prefrontal
R DLPFC 9 38 24 34 69 4.13 <0.001 CET > TAU
R anterior cingulate 10 12 52 10 43 4.67 <0.001 CET > TAU
R DLPFC 46 46 40 16 38 3.49 <0.001 CET > TAU
L caudate – −6 6 8 37 3.55 <0.001 CET > TAU
BA, Brodmann area; MNI, Montreal Neurological Institute; L, left; R, right; CET, Cognitive Enhancement Therapy; TAU, treatment as usual.
Presented results are corrected for multiple comparisons based on 10,000 Monte Carlo simulations executed in AlphaSim (55) using 3dClustSim (α-level of 0.05, k = 34, 
uncorrected p of 0.001).
January 2016 | Volume 6 | Article 1867
Wojtalik et al. CET, Emotion Regulation, Brain Functioning
Frontiers in Psychiatry | www.frontiersin.org
displayed significantly greater activation during the emotion 
regulation task in a large cluster involving the left inferior orbital 
frontal, insula, and ventromedial prefrontal cortices (Table  2; 
Figure 2). Participants treated with CET, compared to TAU, also 
had significantly greater emotion regulation-related activation in 
the right DLPFC, right anterior cingulate cortex, right putamen, 
bilateral caudate, and in a moderately sized cluster in the right 
orbital frontal and right ventromedial prefrontal cortices (Table 2; 
Figure 2). Accordingly, the direction of greater activation related 
to CET during emotion regulation in the above frontolimbic and 
striatal regions may be indicative that CET is contributing to neu-
robiological changes in people with schizophrenia and comorbid 
substance misuse problems.
association Between Posttreatment Brain 
Functioning During emotion regulation 
and longitudinal improvements in 
emotion Processing Behavioral 
Performance
Greater posttreatment activation during the effortful regulation 
of emotion in all regions observed to be significantly different 
between CET and TAU participants (Table 2) were significantly 
correlated with greater longitudinal improvements in MSCEIT 
total scores (all r’s 0.58–0.77, all p <  0.030), with the excep-
tion of the right DLPFC (BA 46 only). Greater longitudinal 
improvement on the ER-40 was significantly correlated with 
greater posttreatment activation in the large cluster involving 
the left inferior orbital frontal, ventromedial prefrontal, and 
insula cortices (r =  0.56, p =  0.037). Greater activation in the 
orbital frontal cortex (cluster including the inferior, middle, 
and superior levels; r = 0.65, p = 0.011) and the right DLPFC 
(BA 9; r = 0.56, p = 0.038) was also significantly associated with 
greater longitudinal improvement on the ER-40. Mediation 
analyses revealed that, when adjusting for treatment assignment, 
greater differential emotion regulation-related activation, favor-
ing CET, in the cluster involving the left inferior orbital frontal, 
ventromedial prefrontal, and insula cortices, had a significant 
direct effect on improved total scores on the MSCEIT, with this 
cluster significantly mediating the association between treatment 
assignment and improved performance on this test (Table 3). No 
direct or mediation effects were observed with regard to changes 
scores on the ER-40.
DiscUssiOn
Substance misuse among people with schizophrenia, especially 
for alcohol and cannabis (2), is a common, significant problem as 
addiction is associated with more severe illness trajectories (11) 
and worse community functioning (6). Poor emotion regulation 
may be a key contributor of elevating the risk for substance mis-
use in individuals with schizophrenia (3, 4). Neural correlates of 
disrupted emotion regulation in individuals with schizophrenia 
and substance misuse problems (52) have been shown to include 
frontal, limbic, and striatal regions important for emotional 
neurocircuitry (22, 23, 36). Recently, significant improvements 
in emotion regulation abilities were observed in individuals with 
schizophrenia who also misuse alcohol and/or cannabis after 
being treated with CET, a cognitive remediation intervention (18). 
Therefore, this original, exploratory study sought to examine dif-
ferences in brain functioning during effortful emotion regulation 
in participants with comorbid schizophrenia and alcohol and/or 
cannabis misuse following CET or TAU. The direct and media-
tion effects of these neurobiological differences on longitudinal 
changes in behavioral emotion processing outcomes were also 
examined.
Compared to participants in TAU, CET participants displayed 
significantly greater activation in frontal, limbic, and striatal 
networks involved in the regulation of emotion at posttreatment 
(22–24, 36, 63), including the DLPFC, ventromedial prefrontal 
cortex, orbital frontal cortex, anterior cingulate, insula, caudate, 
and putamen. No significant interactions were observed regard-
ing emotional valence during the emotional faces n-back task. 
Longitudinal improvements in behavioral emotion processing 
abilities were correlated with greater activation in the majority of 
these above regions. Interestingly, a mediating effect was observed 
in an area including the orbital frontal cortex, ventromedial pre-
frontal cortex, and the insula such that greater brain activation in 
these regions mediated longitudinal improvements in behavioral 
emotion processing abilities.
FigUre 2 | regions of significantly greater activation in participants completing 18 months of ceT, compared to TaU, during the emotional faces 
n-back task.
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Such results suggest that treatment with CET (18) may be 
normalizing the coordination and function of frontolimbic and 
striatal regions involved in emotion regulation in individuals 
with schizophrenia who also misuse alcohol and/or cannabis. 
This is evidenced by research demonstrating that communica-
tion of prefrontal and limbic regions modulates cognitive con-
trol over emotion regulation abilities (64–66), which has been 
observed to be dysregulated in individuals with schizophrenia 
(67, 68). It may be that improved cognitive functioning gained 
through CET (69, 70) increased participants’ ability to regulate 
and manage their emotional states. Meta-analytic evidence has 
shown that cognitive remediation interventions have a com-
mon neural plasticity effect of increasing activation in frontal 
and limbic regions that are related to improved cognitive and 
socio-emotional functioning in individuals with schizophrenia 
(27). The findings from this investigation of increased task-
related activation in some overlapping frontolimbic regions 
are supportive of CET as an effective intervention for sup-
porting functional recovery of this underserved, vulnerable 
population.
Of course, these findings have many caveats that preclude 
firm conclusions regarding causality of treatment efficacy. The 
TaBle 3 | relationships between posttreatment emotion regulation brain 
functioning and longitudinal changes in behavioral emotion processing 
performance.
Direct 
effect
Mediator 
effect
regional clusters B se t df p z′
ΔMSCEIT total score
L inferior orbital frontal
 L insula 14.3 4.3 3.3 11 0.007 −2.7**
 L ventromedial prefrontal
R putamen/caudate 5.6 3.0 1.9 11 0.086 −1.7+
R inferior/middle/superior orbital 
frontal
3.1 2.1 1.5 11 0.169 −1.2
R ventromedial prefrontal
R DLPFC (BA 9) 3.7 2.2 1.7 11 0.116 −1.4
R anterior cingulate 4.3 2.8 1.5 11 0.155 −1.4
R DLPFC (BA 46) 1.4 5.9 0.2 11 0.813 −0.2
L caudate 2.8 1.4 2.1 11 0.062 −1.8+
ΔER-40 correct responses
L inferior orbital frontal
 L insula 1.6 1.3 1.2 11 0.251 −1.2
 L ventromedial prefrontal
R putamen/caudate 0.4 0.8 0.6 11 0.578 −0.6
R inferior/middle/superior orbital 
frontal
0.9 0.5 2.0 11 0.072 −1.6
R ventromedial prefrontal
R DLPFC (BA 9) 0.7 0.5 1.3 11 0.206 −1.1
R anterior cingulate 0.2 0.7 0.3 11 0.764 −0.3
R DLPFC (BA 46) 1.4 1.3 1.1 11 0.292 −0.9
L caudate 0.3 0.4 0.8 11 0.443 −0.8
L, left; R, right; DLPFC, dorsal lateral prefrontal cortex; MSCEIT, The Mayer–Salovey–
Caruso Emotional Intelligence Test; ER-40, Penn Emotion Recognition Test-40.
**p < 0.01.
+p < 1.00.
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first limitation is the very small sample size employed in this 
research, particularly in the TAU condition. This may explain 
the lack of significant emotional valence interactions with group 
assignment from the emotional faces n-back task, although 
sufficient power was available to detect the very large effects 
observed in frontolimbic brain functioning. Also related to the 
small sample size, the groups were not perfectly matched espe-
cially with regard to age and race. Although age and race were 
not significantly different between the groups, we did include 
them as possible confounders in all analyses examining dif-
ferential effects of treatment on brain functioning. Noteworthy, 
CET had a higher, but non-significantly different attrition rate 
compared to TAU in the larger feasibility trial [for a further 
description, see Eack et  al. (18)]. Next, because the imaging 
component was an opportunistic add-on study funded near the 
completion of the parent clinical trial, no pretreatment imaging 
data were available. Posttreatment randomized-controlled trials 
are common and protect against many threats to internal valid-
ity (71), but in the case of quantitative outcomes with unknown 
baseline values, they are unable to determine the magnitude of 
change. We suspect that the greater brain activation observed 
in CET during emotion regulation is reflective of longitudinal 
increases in frontolimbic activity. However, in the absence of an 
active comparison group, such findings may also reflect non-
specific CET effects associated with more therapeutic contacts, 
including group activities. Further, retention of participants for 
fMRI procedures was greater in CET than TAU, which may have 
impacted the results by limiting the sample of TAU participants. 
However, there were no significant differences in baseline char-
acteristics observed between TAU participants who did vs. did 
not complete an fMRI scan (p > 0.166). In addition, we did not 
assess participants level of alcohol and/or cannabis use at the time 
of posttreatment scanning or during assessments of emotion 
processing, which could have influenced brain functioning and 
performance. It will be important for future studies to employ 
longitudinal imaging methods and assess substance misuse at 
the time of assessments to address these issues, and until these 
findings can be replicated in adequately powered samples they 
should be considered tentative and interpreted with caution. It 
will also be important for future research with larger sample 
sizes to examine the implications of such findings on symptom 
severity and other functional outcomes in the illness.
In summary, this preliminary study was the first to show 
a possible neural plasticity relationship between CET and 
emotion regulation-related brain functioning in individu-
als with schizophrenia and alcohol and/or cannabis misuse 
comorbidities participating in a randomized clinical trial. The 
findings indicated that CET may lead to differential changes in 
functioning of frontolimbic and striatal regions implicated in 
the regulation of emotion. Increased activation in these regions 
during effortful emotion regulation was supportive of longitu-
dinal improvements in behavioral emotion processing abilities. 
Improved emotion regulation may serve as a protective factor 
for substance misuse as well as play a role in improved inter-
personal and other psychosocial functioning. The findings from 
this investigation are not only informative for future research 
but also highlight the utility of providing cognitive remediation 
interventions, such as CET, to optimize recovery for people with 
schizophrenia who have substance misuse problems, particularly 
for alcohol and cannabis.
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